Study		Exclusion reasons	Remarks	Reference(s)
Burns, 2022	-	no control group		Burns MD et al. medrxiv;2022.01.05.22268617v1 10.1101/2022.01.05.22268617
Kawasuji, 2022	-	no control group		Kawasuji H et al. medrxiv;2022.02.23.22271433v1 10.1101/2022.02.23.22271433
Falsey, 0	-	no control group		Falsey AR et al. New England Journal of Medicine 10.1056/NEJMc2113468
BioNTech phase 2 (Walsh), 2020	randomized controlled trial	no clinically relevant endpoint	phase 1-2 ; dose-escalation : 13 groups of 15 participants
Molteni, 2022	-	other	modelling study	Molteni E et al. medrxiv;2022.03.13.22272176v1 10.1101/2022.03.13.22272176
Pfizer 16-25 years phase 3, 0	randomized controlled trial	other	very preliminary results from a press release